Recce Pharmaceticals (ASX:RCE) to start clinical trials for topical wound application

Latest Company News - Finance News Network

English - April 15, 2021 06:28 - 1000 KB
Business News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Company News: Whitehaven Coal, Ampol, Alcidion & 92 Energy

Next Episode: Mayne Pharma (ASX:MYX) receives FDA approval for contraceptive pill

15 Apr 2021 - Recce Pharmaceticals’ (ASX:RCE) lead compound RECCE® 327 has been registered in the Australian New Zealand Clinical Trial Registry (ANZCTR) for its Phase I/II Topical Burns Study in humans.